Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Observer Blind, Multinational Phase III Study to Evaluate the Safety and Efficacy of a Nanoemulsion Gel Formulation BF-200 ALA, in Comparison With Metvix® and Placebo, for the Treatment of Actinic Keratosis With PDT

NCT02799069 is registered in ClinicalTrials.gov with Biofrontera Bioscience GmbH as lead sponsor.

NCT NCT02799069
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02799069 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Observer Blind, Multinational Phase III Study to Evaluate the Safety and Efficacy of a Nanoemulsion Gel Formulation BF-200 ALA, in Comparison With Metvix® and Placebo, for the Treatment of Actinic Keratosis With PDT
Lead sponsor
Biofrontera Bioscience GmbH
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2008
Completion date
August 31, 2009
Enrollment
571 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

actinic keratosis